|
| related topics |
| {product, liability, claim} |
| {operation, international, foreign} |
| {competitive, industry, competition} |
| {condition, economic, financial} |
| {property, intellectual, protect} |
| {customer, product, revenue} |
| {regulation, change, law} |
| {acquisition, growth, future} |
|
|
We are subject to a number of existing laws and regulations, non-compliance with which could adversely affect our business, financial condition and results of operations, and we are susceptible to a changing regulatory environment.
Failure to provide quality products and services to our customers could have an adverse effect on our business and subject us to regulatory actions and costly litigation.
If reimbursement for our current or future products is reduced or modified, our business could suffer.
If we are unable to obtain sufficient components and/or raw materials on a timely basis, our business may be adversely affected.
Consolidation in the healthcare industry could adversely affect our business, financial condition and results of operations.
If we are unable to protect our patents or other proprietary rights, or if we infringe on the patents or other proprietary rights of others, our competitiveness and business prospects may be materially damaged.
If our business development activities are unsuccessful, our business could suffer and our financial performance could be adversely affected.
If we are unsuccessful in identifying growth opportunities or if we are unsuccessful in exiting low margin businesses or discontinuing low profit products, our business, financial condition and results could be adversely affected.
We face substantial competition and many of our competitors have significantly greater financial and other resources.
We are subject to risks associated with doing business globally.
We are subject to foreign currency exchange risk.
Current challenges in the commercial and credit environment may adversely affect our business and financial condition.
Full 10-K form ▸
|
|
| related documents |
| 874716--2/19/2010--IDEXX_LABORATORIES_INC_/DE |
| 1110783--10/26/2007--MONSANTO_CO_/NEW/ |
| 736822--7/27/2007--IMMUCOR_INC |
| 10081--2/29/2008--BARR_PHARMACEUTICALS_INC |
| 780127--1/12/2007--SYNOVIS_LIFE_TECHNOLOGIES__INC |
| 739944--3/15/2007--MEDTOX_SCIENTIFIC_INC |
| 874710--9/26/2008--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 874710--9/28/2007--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 313143--5/27/2008--HAEMONETICS_CORP |
| 874710--9/28/2006--ALLIED_HEALTHCARE_PRODUCTS_INC |
| 10456--2/23/2010--BAXTER_INTERNATIONAL_INC |
| 739944--3/11/2008--MEDTOX_SCIENTIFIC_INC |
| 739944--3/17/2006--MEDTOX_SCIENTIFIC_INC |
| 874716--2/20/2009--IDEXX_LABORATORIES_INC_/DE |
| 1050007--11/30/2006--NUTRACEUTICAL_INTERNATIONAL_CORP |
| 57725--9/13/2006--LANNETT_CO_INC |
| 739944--3/10/2009--MEDTOX_SCIENTIFIC_INC |
| 10795--11/24/2010--BECTON_DICKINSON_&_CO |
| 768408--6/24/2010--CYANOTECH_CORP |
| 275053--3/16/2010--NATURES_SUNSHINE_PRODUCTS_INC |
| 862668--9/29/2008--ESCALON_MEDICAL_CORP |
| 929987--2/22/2006--GUIDANT_CORP |
| 810084--4/2/2007--BIOJECT_MEDICAL_TECHNOLOGIES_INC |
| 912093--8/31/2010--JDS_UNIPHASE_CORP_/CA/ |
| 880432--9/28/2009--MISONIX_INC |
| 59440--3/17/2006--VECTOR_GROUP_LTD |
| 862668--10/12/2010--ESCALON_MEDICAL_CORP |
| 102037--5/27/2010--UNIVERSAL_CORP_/VA/ |
| 736822--7/24/2008--IMMUCOR_INC |
| 26172--2/27/2007--CUMMINS_INC |
|